AEG

Unpacking the Momentum Behind Aegon Stock

Aegon shares rose 3.2% this morning to a price of $6.49. The stock is still trading within range of its average target price of $6.8, and over the last 52 weeks, it has recorded a 18.0% performance. Analysts have given the Large-Cap Life Insurance stock target prices ranging from $6.2 to $7.40005 dollars per share, with an average rating of buy.

Aegon's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.3%. The stock's short ratio is 1.24. At 0.0%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.

Another number to watch is the company's rate of institutional share ownership, which now stands at 9.8%. In conclusion, we believe there is mixed market sentiment regarding Aegon.

Institutions Invested in Aegon

Date Reported Holder Percentage Shares Value
2024-09-30 Dodge & Cox Inc 7% 117,784,082 $764,418,665
2024-06-30 Arrowstreet Capital, Limited Partnership 0% 8,367,194 $54,303,087
2024-09-30 Morgan Stanley 0% 6,510,256 $42,251,559
2024-09-30 Blackrock Inc. 0% 5,396,180 $35,021,206
2024-09-30 Dimensional Fund Advisors LP 0% 5,114,928 $33,195,881
2024-09-30 Goldman Sachs Group Inc 0% 4,490,807 $29,145,336
2024-09-30 Wellington Management Group, LLP 0% 4,484,791 $29,106,292
2024-09-30 Raymond James & Associates, Inc. 0% 2,517,071 $16,335,790
2024-09-30 Grace & White Inc /ny 0% 1,493,962 $9,695,813
2024-09-30 Voloridge Investment Management, LLC 0% 1,486,148 $9,645,100
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS